Prevalence of Low Plasma IGF‐I in Poliomyelitis Survivors

Abstract

Lower levels of IGF-I are seen in polio survivors, and this finding correlates with ADL dysfunction. The hyposomatomedinemic tendency of polio survivors may have an adverse effect on their neuromuscular function and quality of life.

Insulin growth factors may explain relationship between spasticity and skeletal muscle size in men with spinal cord injury

“…A possible explanation is that spasticity maintained the IGF-1 profile despite lower GH. This observation is confirmed by another finding that clearly documented that persons with poliomyelitis have diminished IGF-1 profiles [20]. Persons with poliomyelitis commonly experience flaccid paralysis due to injury of their alpha motor neurons.…”

Prediction of voluntary activation, strength and endurance of elbow flexors in postpolio patients

“…In the present study, mean levels of IGF-1 in patients were not abnormal and there was no significant correlation between IGF-1 levels and maximal 31,33 A recent study reports a negative correlation between muscle force and IGF-1 levels. 38 Serum creatine kinase levels were mildly increased in prior-polio patients.…”

“…It remains to be determined whether decreased levels of IGF-1 are linked to impairment in voluntary activation in these patients and whether the maximal level of voluntary activation improves when IGF-1 levels are increased. 31,33,35,38 Some investigators 40,42 have found increased serum creatine kinase levels in postpolio patients. Therefore, we hypothesized that IGF-1 and creatine kinase may predict impaired voluntary activation and impaired endurance, respectively.…”

Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis

“…In a pilot study of 10 PPS patients Shetty KR et al [17] reported the mean serum [IGF-I] to be approximately 50% lower than age matched controls. A larger study by Rao et al [18] of 124 PPS patients and 261 age matched controls also reported a 25% lower mean [IGF-I] in the PPS patients. The authors considered this to be indicative of an overall reduction in peripheral IGF bioactivity.…”

“…The absence of detailed information on the endogenous peripheral IGF system in disease states may be one of the limitations in the design of these clinical trials. To date, conflicting studies of the circulating IGFs report normal or decreased levels of IGF-I in ALS [13][14][15] and post polio syndrome (PPS) [16][17][18] but unchanged levels of IGF-I in MS [14,[19][20][21].…”